AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01550302 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superficial Cervical Plexus Block
Description: At the end of the lung surgery while subjects are still under general anesthesia, one of the investigators will perform superficial cervical plexus. First, a line extending from the mastoid process to C6 transverse process is drawn. The site of needle insertion is marked at the midpoint of the line connecting the mastoid process with Chassaignac's tubercle of C6 transverse process. After skin cleansing with chlorhexidine prep, using a fan technique with superior-inferior needle redirections, 15 ml of 0.25% bupivacaine will be injected alongside the posterior border of the sternocleidomastoid muscle 2-3 cm below and above the needle insertion site.
Study NCT01550302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Single dose of 37.5 mg of bupivacaine subcutaneously
Study NCT02343627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVXT Solution
Description: NVXT Solution, applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
Study NCT01541540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Counseling plus Usual Care
Description: 28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12. Each email will contain an e-link to lifestyle counseling activities designed to enhance motivation and skill to initiate and maintain lifestyle change. e-Counseling includes video-based education and counseling as well as e-tools to self-monitor and reinforce adherence to self-management behavior for exercise, diet, prescribed medications and smoke-free living.
Study NCT01541540 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive general educational material on heart healthy living. 28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12.
Study NCT00621244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study NCT04644679 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 7-day electrocardiographic monitoring
Description: 7-day external electrocardiographic monitoring
Study NCT04644679 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 48-hr electrocardiographic monitoring
Description: 48-hr external electrocardiographic monitoring
Study NCT03202992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1968
Description: Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
Study NCT03394534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGA group
Description: CGA Plus Individualised Care and Support Plan delivered by Advanced Clinical Practitioner (ACP)
Study NCT03245840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide oral suspension
Description: BOS 10 mL twice daily.
Study NCT02111954 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9
Description: Each patient will have two PET/CT
Study NCT04913792 — intervention group
Intervention type: DEVICE
Intervention: ZXR00
Description: This prospective comparative study included 60 eyes undergoing cataract surgery with implantation of an extended range of vision IOL.(Abbott Medical Optics, Inc.)
Study NCT01555073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin/placebo
Description: pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.
Study NCT01555073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib/placebo
Description: celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.
Study NCT01555073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo group, two placebo tablets day of surgery and twice a day for 13 days
Study NCT04387695 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT+TACE+Sorafenib
Description: SBRT first for the PVTT +TACE for HCC within a week next +Sorafenib with 2 weeks later
Study NCT04387695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib 800 mg/day orally
Study NCT02340858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife LEDC System
Description: Irreversible electroporation (IRE) is a method to induce irreversible disruption of cell membrane integrity (loss of cell homeostasis) resulting in cell death without the need for additional pharmacological injury. Because IRE is a non-thermal technique, changes associated with perfusion-mediated tissue cooling (or heating) are not relevant. While cells in the ablation region are destroyed, the underlying extracellular matrix is not damaged thus allowing tissues in the ablation zone to heal normally.
Study NCT04475523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-8993
Description: CI-8993 is a fully human immunoglobulin (Ig) G1κ monoclonal antibody (mAb) against the VISTA ligand
Study NCT03287882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (UNIMMAP composition)
Description: The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.
Study NCT03287882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life skills based education
Description: The life skills based education will be provided bi-monthly in the format of a group session throughout the preconception period. Three topic areas related to empowerment have been prioritized, including preventing early marriage; personal and menstrual hygiene practices; and the importance of nutrition to good health. Integrated within these topics will be messages related to the importance of continuing one's education, mental health, gender norms and equality, decision making, advocacy, resiliency, participation, communication skills, facing challenges, agency, conflict resolution, and the prevention of violence.
Study NCT01437579 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intratrigonal injection of botulinum toxin
Description: Bladder intratrigonal injection of botulinum toxin during cystoscopy under general anesthesia
Study NCT01437579 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: cystoscopy
Description: cystoscopy under general anesthesia
Study NCT02600416 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: AV port reversal
Description: Reversal of the AV port at 1h Reversal of the AV port to start position at 7h
Study NCT02705846 — intervention group
Intervention type: OTHER
Intervention: Observation of treatment outcomes via Questionnaire
Description: Collection of treatment data from participants
Study NCT01978054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dissemination of public health knowledge
Description: State health department chronic disease units will be involved with developing and choosing dissemination activities to spread public health knowledge and information on population-based public health strategies that have been shown to reduce risk factors for cancer and other chronic diseases. Example of activities include: multi-day in-person training workshops and electronic information exchange modalities.
Study NCT02302248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crowdsourcing reappraisal intervention
Description: 3 week access to a web-based crowdsourcing reappraisal platform.
Study NCT02302248 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expressive writing intervention
Description: 3 week access to a web-based expressive writing platform.
Study NCT03049358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiologic Testing
Description: Undergo UPSIT smell test
Study NCT03049358 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physiologic Testing
Description: Undergo UPSIT smell test
Study NCT03049358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03049358 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03049358 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Undergo sham training
Study NCT03049358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Procedure
Description: Undergo olfactory training
Study NCT03049358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rose essential oil
Description: patient smells rose oil in vial
Study NCT03049358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lemon essential oil
Description: patient smells lemon oil in vial
Study NCT03049358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clove essential oil
Description: patient smells clove oil in vial
Study NCT03049358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eucalyptus essential oil
Description: patient smells eucalyptus oil in vial
Study NCT03049358 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: canola oil placebo
Description: patient smells canola oil in vial
Study NCT04966312 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative educational videos plus routine education
Description: Mothers receiving routine education plus digital video disk before their children receiving congenital heart disease surgery. The content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
Study NCT04966312 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative routine education
Description: Mothers receiving routine education before their children receiving congenital heart disease surgery
Study NCT02027311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
Study NCT02027311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
Study NCT02027311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperidine
Description: Both groups were administered same dose of meperidinie 50mg. Then elders > 80 years old were administered 25mg iv bolus.
Study NCT01114087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Description: Imatinib is a tyrosin-kinase inhibitor
Study NCT00887367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK598809
Description: Two 175 mg doses of GSK598809 will be given.
Study NCT00887367 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol
Description: A constant ethanol level of 0.6 g·L-1 for five hours will be given to the subjects intravenously. This level shows significant CNS effects, without causing too many inadvertent events. Furthermore this level is considered safe as it is just above the legal driving limit in the Netherlands (i.e. 0.5 g·L-1) and these levels are routinely achieved during social drinking. Moreover, this level leaves enough room for CNS-impairment without compromising safety, in case of a (supra-) addictive drug-alcohol interaction.
Study NCT01679600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feedback-controlled robotics-assisted treadmill exercise
Description: Progressive cardiovascular exercise using feedback-controlled robotics-assisted treadmill exercise. The first training session is defined to start at 40% of peak work rate (determined from a previous exercise test) to approach 40% of heart rate reserve (Borg scale approximately 11-14). The intensity will then be adjusted on the basis of continuous heart rate data and rating of perceived exertion indications by modulating the target work rate in 5% increments for every subsequent session to reach the target intensity. The target heart rate is set at 40% to 70% of heart rate reserve.
Study NCT01679600 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotics-assisted treadmill exercise
Description: Conventional robotics-assisted treadmill exercise, where therapists focus on gait quality only.
Study NCT01496326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 10% ibuprofen cream formulation at a dose of 200mg
Study NCT01496326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 grams of placebo cream for 14 days
Study NCT04334135 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: Four to eight 20mg capsules (depending on body mass)
Study NCT04334135 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MitoQ
Description: Four to eight 20mg capsules (depending on body mass)
Study NCT05999058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dacryoendoscopic-assisted laser dacryoplasty with silicone intubation
Description: The dacryoendoscopy was inserted into the lacrimal duct through the upper or lower lacrimal punctum. When the dacryoendoscopy reached the postsaccal obstruction, laser dacryoplasty (FOX diode laser, A.R.C. Laser, Nürnberg, Germany) was performed by widening the stenotic or obstructed section. After removing the dacryoendoscopy, a silicone tube inserted into lacrimal passage. Double bicanalicular silicone intubation was performed as previously described.
Study NCT02343627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of test product
Description: Vehicle of test product applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
Study NCT03403660 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non White coat
Description: Postpartum patients are randomized to either arm of the study (white coat or standard scrub suit only) by location. All the obstetric physicians associated with patient's postpartum care should use or not use white coat in every single encounter with patient.
Study NCT00202436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotomy
Description: Removal of 500 ml whole blood
Study NCT00202436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erythrocytapheresis
Description: machinal removal of erythrocytes
Study NCT04095884 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling
Description: observational study and no intervention will be given. only blood samples collected and treated with iron supplements
Study NCT00862706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine/LDT600A
Description: Oral once daily
Study NCT03155113 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood drawing
Description: Before starting therapy a blood sample will be collected from any subject.
Study NCT05397262 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyperthermia
Description: Deep Regional Hyperthermia (RHT) 1-2/week up to 10 sessions a type of cancer treatment in which body tissue is exposed to high temperatures (up to 113°F).
Study NCT05397262 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: 50,4 Gy (28 x 1,8 Gy) plus Boost: If R0: 5,4 Gy; If R1/2: 9 Gy
Study NCT05397262 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy 5-Fluorouracil
Description: 600 mg/m\^2 civ 120h; d 1-5, 29-33
Study NCT05397262 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy Cisplatin
Description: 20 mg/m\^2; d1-5, 29-33
Study NCT02259049 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-tyrosine
Description: Each subject will receive 2,000 mg of L-tyrosine BID for 24 hours.
Study NCT02259049 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-tyrosine
Description: Each subject will receive 2,000 mg of L-tyrosine BID for 24 hours.
Study NCT02259049 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sugar Pill
Description: Each subject will receive a sugar pill BID for 24 hours.
Study NCT02259049 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Each subject will receive a sugar pill BID for 24 hours.
Study NCT03901989 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: zeolite
Description: given for a period of 12 months
Study NCT03901989 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cellulose
Description: given for a period of 12 months
Study NCT01354444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: target dose of 25 mg daily which is half the maximum dose used in clinical practice
Study NCT01354444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a pill that will look like the active drug but will not contain any carvedilol
Study NCT02854241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biannual ultrasonography
Description: Biannual ultrasonography for HCC surveillance, performed by board-certified radiologists.
Study NCT02854241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Annual noncontrast liver MRI
Description: Annual noncontrast liver MRI consisted of T2WI, precontrast T1WI, dual-echo image, DWI (single shot, multishot) and T2 map.~DWI using multishot and T2 map are not included for initial MR reading.
Study NCT02854241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast enhanced liver CT
Description: In patients without report of HCC during surveillance period, contrast CT is performed 6 months after the last MR scan.
Study NCT03035084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Single oral dose of 50,000 IU of vitamin D3
Study NCT00735306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin 10 mg/kg IV on days 1, 15 and 29 Begins the first day of radiation therapy
Study NCT00735306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: Daily by mouth per assigned dose, for 5.5 weeks Begins the first day of radiation therapy
Study NCT00735306 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation to the pancreas Monday through Friday for 28 treatments
Study NCT02784873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: High intensity interval training within a standard cardiac rehabilitation programme
Study NCT03902730 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Back Squat
Description: Participants will complete traditional back squat in this four treatment crossover design.
Study NCT03902730 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Barefoot Back Squat
Description: Participants will complete barefoot back squat in this four treatment crossover design.
Study NCT03612674 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard colonoscopy
Description: Current standard of care colonoscopy.
Study NCT03612674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARC Endocuff Vision
Description: Subjects randomized to undergo a colonoscopy procedure with ARC Endocuff Vision will have this device placed on the top of the colonoscope used during their procedure.
Study NCT01807494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip replacement components
Description: All patients will receive the same implants
Study NCT03902730 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Box Squat
Description: Participants will complete box squat in this four treatment crossover design.
Study NCT03902730 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Back Squat with Chains
Description: Participants will complete traditional back squat with chains in this four treatment crossover design.
Study NCT03219554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
Study NCT04229173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI acquisition
Description: MRI acquisition
Study NCT04229173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: DAT-SPECT
Description: Imaging with DAT SPECT (Dopamine Transporter, Single Photon Emission Computed Tomography)
Study NCT03035084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Description: Single oral dose of 50,000 IU of vitamin D2
Study NCT03035084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D2
Description: Single oral dose of 50,000 IU of vitamin D2